EE177 Economic Impact of Contrast-Induced Nephropathy in Percutaneous Coronary Intervention: A Medicare Payer Perspective

Contrast-induced nephropathy (CIN) is a common and morbid complication of percutaneous coronary intervention (PCI), occurring in up to 5% of patients. CIN after PCI not only increases the morbidity/mortality risk, but is also associated with a large potential impact on costs, particularly in elderly Medicare patients. Our objective was to estimate the short- and long-term economic impact of CIN in Medicare patients undergoing PCI.